{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:31:17Z","timestamp":1772811077386,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T00:00:00Z","timestamp":1414627200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40801-014-0005-2","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T08:43:08Z","timestamp":1414572188000},"page":"7-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan"],"prefix":"10.1007","volume":"1","author":[{"given":"Satoshi","family":"Asakura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hosokai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Kajii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,30]]},"reference":[{"issue":"5","key":"5_CR1","first-page":"951","volume":"14","author":"M Murakami","year":"1998","unstructured":"Murakami M, Mori A, Miura S, Kurihara M, Yamashita I, Asai M, et al. Clinical evaluation of SME3110 (fluvoxamine maleate), a selective serotonin reuptake inhibitor, in depression or depressive state: a double blind study versus amitriptyline hydrochloride [in Japanese]. Rinsho Iyaku. 1998;14(5):951\u201380.","journal-title":"Rinsho Iyaku."},{"issue":"4","key":"5_CR2","first-page":"651","volume":"12","author":"M Namiki","year":"1996","unstructured":"Namiki M, Muto E, Minemoto H, Ishikawa Y, Okuse T, Hisamura M, et al. A phase III clinical study of SME3110 (fluvoxamine maleate) in depression in the field of internal medicine: a double blind study versus trazodone hydrochloride [in Japanese]. Rinsho Iyaku. 1996;12(4):651\u201377.","journal-title":"Rinsho Iyaku."},{"issue":"3","key":"5_CR3","first-page":"471","volume":"12","author":"I Oka","year":"1996","unstructured":"Oka I, Ito K, Narita H, Matsubara S, Matsubara R. Clinical evaluation of SME3110 (fluvoxamine maleate) in depression and depressive state: a long-term treatment study [in Japanese]. Rinsho Iyaku. 1996;12(3):471\u201387.","journal-title":"Rinsho Iyaku."},{"issue":"4","key":"5_CR4","first-page":"679","volume":"12","author":"T Nakajima","year":"1996","unstructured":"Nakajima T, Kudo Y, Yamashita I, Asai M, Kamijima K, Murasaki M, et al. A long-term treatment study of fluvoxamine maleate (SME3110), a selective serotonin reuptake inhibitor, in obsessive-compulsive disorder [in Japanese]. Rinsho Iyaku. 1996;12(4):679\u2013700.","journal-title":"Rinsho Iyaku."},{"issue":"3","key":"5_CR5","first-page":"589","volume":"14","author":"T Nakajima","year":"1998","unstructured":"Nakajima T, Kudo Y, Yamashita I, Asai M, Kamijima K, Murasaki M, et al. A late phase II clinical study of fluvoxamine maleate (SME3110), a selective serotonin reuptake inhibitor, in obsessive-compulsive disorder [in Japanese]. Rinsho Iyaku. 1998;14(3):589\u2013616.","journal-title":"Rinsho Iyaku."},{"issue":"2","key":"5_CR6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1017\/S1461145706006602","volume":"10","author":"S Asakura","year":"2007","unstructured":"Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2007;10(2):263\u201374.","journal-title":"Int J Neuropsychopharmacol."},{"issue":"11","key":"5_CR7","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1176\/appi.ps.60.11.1439","volume":"60","author":"BN Gaynes","year":"2009","unstructured":"Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439\u201345.","journal-title":"Psychiatr Serv."},{"issue":"2","key":"5_CR8","doi-asserted-by":"crossref","first-page":"e55448","DOI":"10.1371\/journal.pone.0055448","volume":"8","author":"N Hoertel","year":"2013","unstructured":"Hoertel N, Le Strat Y, Limosin F, Dubertret C, Gorwood P. Prevalence of subthreshold hypomania and impact on internal validity of RCTs for major depressive disorder: results from a national epidemiological sample. PLoS One. 2013;8(2):e55448.","journal-title":"PLoS One."},{"issue":"8","key":"5_CR9","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.4088\/JCP.v69n0810","volume":"69","author":"C Blanco","year":"2008","unstructured":"Blanco C, Olfson M, Goodwin RD, Ogburn E, Liebowitz MR, Nunes EV, et al. Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2008;69(8):1276\u201380.","journal-title":"J Clin Psychiatry."},{"issue":"3","key":"5_CR10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jad.2012.09.023","volume":"146","author":"N Hoertel","year":"2013","unstructured":"Hoertel N, Le Strat Y, De Maricourt P, Limosin F, Dubertret C. Are subjects in treatment trials of panic disorder representative of patients in routine clinical practice? Results from a national sample. J Affect Disord. 2013;146(3):383\u20139.","journal-title":"J Affect Disord."},{"issue":"7","key":"5_CR11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/da.21937","volume":"29","author":"N Hoertel","year":"2012","unstructured":"Hoertel N, Le Strat Y, Blanco C, Lavaud P, Dubertret C. Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depress Anxiety. 2012;29(7):614\u201320.","journal-title":"Depress Anxiety."},{"issue":"3","key":"5_CR12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1176\/appi.ajp.159.3.469","volume":"159","author":"M Zimmerman","year":"2002","unstructured":"Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;159(3):469\u201373.","journal-title":"Am J Psychiatry."},{"issue":"7","key":"5_CR13","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1176\/appi.ajp.162.7.1370","volume":"162","author":"M Zimmerman","year":"2005","unstructured":"Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry. 2005;162(7):1370\u20132.","journal-title":"Am J Psychiatry."},{"key":"5_CR14","doi-asserted-by":"crossref","unstructured":"Hoertel N, de Maricourt P, Katz J, Doukhan R, Lavaud P, Peyre H, et al. Are participants in pharmacological and psychotherapy treatment trials for social anxiety disorder representative of patients in real-life settings? J Clin Psychopharmacol. 2014 [Epub ahead of print].","DOI":"10.1097\/JCP.0000000000000204"},{"issue":"6","key":"5_CR15","first-page":"224","volume":"54","author":"LK Laird","year":"1993","unstructured":"Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J Clin Psychiatry. 1993;54(6):224\u20138.","journal-title":"J Clin Psychiatry."},{"issue":"2","key":"5_CR16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00004714-199604000-00003","volume":"16","author":"JL Claghorn","year":"1996","unstructured":"Claghorn JL, Earl CQ, Walczak DD, Stoner KA, Wong LF, Kanter D, Houser VP. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol. 1996;16(2):113\u201320.","journal-title":"J Clin Psychopharmacol."},{"issue":"1\u20132","key":"5_CR17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02244762","volume":"115","author":"IM Vliet van","year":"1994","unstructured":"van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl). 1994;115(1\u20132):128\u201334.","journal-title":"Psychopharmacology (Berl)."},{"issue":"5","key":"5_CR18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.156.5.756","volume":"156","author":"MB Stein","year":"1999","unstructured":"Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999;156(5):756\u201360.","journal-title":"Am J Psychiatry."},{"issue":"4","key":"5_CR19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S146114570300364X","volume":"6","author":"DJ Stein","year":"2003","unstructured":"Stein DJ, Westenberg HG, Yang H, Li D, Barbato LM. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol. 2003;6(4):317\u201323.","journal-title":"Int J Neuropsychopharmacol."},{"issue":"Suppl 12","key":"5_CR20","first-page":"14","volume":"67","author":"MB Keller","year":"2006","unstructured":"Keller MB. Social anxiety disorder clinical course and outcome: review of Harvard\/Brown Anxiety Research Project (HARP) findings. J Clin Psychiatry. 2006;67(Suppl 12):14\u20139.","journal-title":"J Clin Psychiatry."},{"issue":"8","key":"5_CR21","first-page":"773","volume":"33","author":"M Asakura","year":"2005","unstructured":"Asakura M, Tajima O. A randomized, double-blind study of fluvoxamine maleate in patents with depression or depressive state: a comparison in anticholinergic effects and cardiovascular adverse reactions between fluvoxamine maleate and imipramine hydrochloride [in Japanese]. Jpn Pharmacol Ther. 2005;33(8):773\u201387.","journal-title":"Jpn Pharmacol Ther."},{"key":"5_CR22","unstructured":"United States Food and Drug Administration (FDA). Antidepressant use in children, adolescents, and adults. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/InformationbyDrugClass\/ucm096273 . Accessed 30 May 2013."},{"issue":"7217","key":"5_CR23","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.319.7217.1106","volume":"319","author":"FJ Abajo de","year":"1999","unstructured":"de Abajo FJ, Rodr\u00edguez LA, Motero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319(7217):1106\u20139.","journal-title":"BMJ."},{"issue":"1","key":"5_CR24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archinte.163.1.59","volume":"163","author":"SO Dalton","year":"2003","unstructured":"Dalton SO, Johansen C, Mellemkjer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding. Arch Intern Med. 2003;163(1):59\u201364.","journal-title":"Arch Intern Med."},{"issue":"2","key":"5_CR25","first-page":"187","volume":"45","author":"K Tada","year":"2003","unstructured":"Tada K, Uehara J, Matsuda E, Suzuki T, Watanabe M, Kojima T. Three cases of serious gastrointestinal hemorrhage during treatment with SSRIs and NSAIDs [in Japanese]. Seishin Igaku. 2003;45(2):187\u20139.","journal-title":"Seishin Igaku."},{"issue":"6","key":"5_CR26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1055\/s-2007-979612","volume":"28","author":"HM Hochberg","year":"1995","unstructured":"Hochberg HM, Kanter D, Houser VP. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience. Pharmacopsychiatry. 1995;28(6):253\u20136.","journal-title":"Pharmacopsychiatry."},{"key":"5_CR27","unstructured":"Pharmaceuticals and Medical Devices Agency. Information on case reports of possible adverse drug reactions [in Japanese]. http:\/\/www.info.pmda.go.jp\/fsearchnew\/jsp\/menu_fukusayou_base.jsp . Accessed 30 May 2013."},{"issue":"Suppl 3","key":"5_CR28","first-page":"10","volume":"62","author":"AL Montejo","year":"2001","unstructured":"Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62(Suppl 3):10\u201321.","journal-title":"J Clin Psychiatry."},{"issue":"8","key":"5_CR29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.280.8.708","volume":"280","author":"MB Stein","year":"1998","unstructured":"Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280(8):708\u201313.","journal-title":"JAMA."},{"issue":"3","key":"5_CR30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0447.1999.tb10845.x","volume":"100","author":"C Allgulander","year":"1999","unstructured":"Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand. 1999;100(3):193\u20138.","journal-title":"Acta Psychiatr Scand."},{"key":"5_CR31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.175.2.120","volume":"175","author":"D Baldwin","year":"1999","unstructured":"Baldwin D, Bobes J, Stein DJ, Scharw\u00e4chter I, Faure M. Paroxetine in social phobia\/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999;175:120\u20136.","journal-title":"Br J Psychiatry."},{"issue":"9","key":"5_CR32","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1176\/ajp.152.9.1368","volume":"152","author":"DJ Katzelnick","year":"1995","unstructured":"Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995;152(9):1368\u201371.","journal-title":"Am J Psychiatry."},{"issue":"2","key":"5_CR33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1176\/appi.ajp.158.2.275","volume":"158","author":"MA Ameringen Van","year":"2001","unstructured":"Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001;158(2):275\u201381.","journal-title":"Am J Psychiatry."},{"issue":"Suppl 12","key":"5_CR34","first-page":"20","volume":"67","author":"JR Davidson","year":"2006","unstructured":"Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006;67(Suppl 12):20\u20136.","journal-title":"J Clin Psychiatry."},{"key":"5_CR35","first-page":"203","volume":"8","author":"J Canton","year":"2012","unstructured":"Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012;8:203\u201315.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"1\u20133","key":"5_CR36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jad.2010.08.025","volume":"129","author":"H Rodrigues","year":"2011","unstructured":"Rodrigues H, Figueira I, Gon\u00e7alves R, Mendlowicz M, Macedo T, Ventura P. CBT for pharmacotherapy non-remitters\u2014a systematic review of a next-step strategy. J Affect Disord. 2011;129(1\u20133):219\u201328.","journal-title":"J Affect Disord."},{"key":"5_CR37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1756-0500-6-74","volume":"6","author":"N Yoshinaga","year":"2013","unstructured":"Yoshinaga N, Ohshima F, Matsuki S, Tanaka M, Kobayashi T, Ibuki H, et al. A preliminary study of individual cognitive behavior therapy for social anxiety disorder in Japanese clinical settings: a single-arm, uncontrolled trial. BMC Res Notes. 2013;6:74.","journal-title":"BMC Res Notes."},{"key":"5_CR38","doi-asserted-by":"crossref","unstructured":"Yoshinaga N, Niitsu T, Hanaoka H, Sato Y, Ohshima F, Matsuki S, et al. Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting: a randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment. BMJ Open. 2013;3(2). doi: 10.1136\/bmjopen-2012-002242 .","DOI":"10.1136\/bmjopen-2012-002242"},{"issue":"11","key":"5_CR39","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.4088\/JCP.v66n1102","volume":"66","author":"BF Grant","year":"2005","unstructured":"Grant BF, Hasin DS, Blanco C, Stinson FS, Chou SP, Goldstein RB, et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66(11):1351\u201361.","journal-title":"J Clin Psychiatry."},{"issue":"4","key":"5_CR40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/da.10112","volume":"17","author":"FR Schneier","year":"2003","unstructured":"Schneier FR, Blanco C, Campeas R, Lewis-Fernandez R, Lin SH, Marshall R, et al. Citalopram treatment of social anxiety disorder with comorbid major depression. Depress Anxiety. 2003;17(4):191\u20136.","journal-title":"Depress Anxiety."},{"issue":"Suppl 22","key":"5_CR41","first-page":"29","volume":"60","author":"JC Ballenger","year":"1999","unstructured":"Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999;60(Suppl 22):29\u201334.","journal-title":"J Clin Psychiatry."},{"issue":"1\u20133","key":"5_CR42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2011.12.008","volume":"137","author":"MK Hofmeijer-Sevink","year":"2012","unstructured":"Hofmeijer-Sevink MK, Batelaan NM, van Megen HJ, Penninx BW, Cath DC, van den Hout MA, et al. Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord. 2012;137(1\u20133):106\u201312.","journal-title":"J Affect Disord."},{"issue":"4","key":"5_CR43","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/da.20043","volume":"20","author":"DJ Stein","year":"2004","unstructured":"Stein DJ, Kasper S, Andersen EW, Nil R, Lader M. Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions. Depress Anxiety. 2004;20(4):175\u201381.","journal-title":"Depress Anxiety."},{"issue":"3","key":"5_CR44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hup.1106","volume":"5","author":"I Hindmarch","year":"2010","unstructured":"Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol. 2010;5(3):193\u2013200.","journal-title":"Hum Psychopharmacol."},{"issue":"2","key":"5_CR45","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbr.2009.12.043","volume":"221","author":"A Waarde van","year":"2011","unstructured":"van Waarde A, Ramakrishnan NK, Rybczynska AA, Elsinga PH, Ishiwata K, et al. The cholinergic system, sigma-1 receptors and cognition. Behav Brain Res. 2011;221(2):543\u201354.","journal-title":"Behav Brain Res."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40801-014-0005-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-014-0005-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-014-0005-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T17:26:06Z","timestamp":1689614766000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40801-014-0005-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,30]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["5"],"URL":"https:\/\/doi.org\/10.1007\/s40801-014-0005-2","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,30]]}}}